Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis
BIO 300 的开发作为特发性肺纤维化的新型治疗方法
基本信息
- 批准号:10603367
- 负责人:
- 金额:$ 29.85万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAdoptionAffectAgeBiological MarkersBiological ModelsBleomycinCancer PatientChestCicatrixClinicClinicalClinical ResearchCollagenCombined Modality TherapyDataDepositionDevelopmentDiagnosisDiseaseDisease ProgressionDoseDose LimitingDrug KineticsDyspneaExhibitsExposure toFDA approvedFatigueFeedbackFoundationsFutureGasesGene ExpressionGenisteinGoalsHistopathologyIn VitroIncidenceInflammatoryInflammatory InfiltrateIonizing radiationLifeLungLung ComplianceLung diseasesMalignant neoplasm of lungMeasuresMediatorModelingMultiple Organ FailureMusNon-Small-Cell Lung CarcinomaOralOutcomePatientsPersonsPharmaceutical PreparationsPhasePirfenidonePre-Clinical ModelPrognosisPulmonary FibrosisPulmonary HypertensionPulmonary InflammationQuality of lifeRadiationRadiation Therapy Oncology GroupRadiation therapyReportingResearchRespiratory FailureSafetySerumSmall Business Innovation Research GrantSuspensionsSystemTGF Beta Signaling PathwayTherapeuticTimeTissuesToxic effectTranslationsTreatment EfficacyUnited StatesWorkantifibrotic treatmentclinical developmenteffective therapyfunctional disabilityhealthy volunteeridiopathic pulmonary fibrosisimprovedin vivo Modelindium-bleomycinlung injurymeetingsmenmouse modelnanonanoparticlenext generationnintedanibnovelnovel therapeuticspatient tolerabilitypre-clinicalpreventpulmonary functionpulmonary function declinereduce symptomsresearch clinical testingside effecttreatment effecttumor
项目摘要
Project Summary
Idiopathic pulmonary fibrosis (IPF) is a serious lung disease characterized by progressive scarring of the tissue
in the lungs. IPF is associated with a particularly poor prognosis with most patients succumbing to the disease
within 3-5 years from the time of diagnosis. Two antifibrotic therapies, nintedanib and pirfenidone, have been
approved in recent years for the treatment for IPF based on their ability to slow the rate of decline in lung function
in patients, however, neither treatment have been shown to lead to meaningful improvements in patient quality
of life, and both have issues with patient tolerability.
Humanetics is developing BIO 300, a nanosuspension of synthetic genistein, as a therapy to mitigate pulmonary
fibrosis resulting from exposure of the lungs to ionizing radiation. Genistein has been shown to exhibit antifibrotic
activity in a variety of in vitro and in vivo model systems through its inhibition of proinflammatory and profibrotic
gene expression induced by activation of the canonical NF-κB and TGF-β signaling pathways. Based on these
findings, we hypothesize that BIO 300 may have significant therapeutic potential as a therapy for IPF patients.
Importantly, BIO 300 has demonstrated an exceptional clinical safety profile in clinical studies in both healthy
volunteers and lung cancer patients undergoing radiotherapy, which will streamline its path toward future clinical
evaluation as an IPF treatment.
The goal of this phase 1 SBIR project is to evaluate the utility of BIO 300 as a treatment for IPF by measuring its
ability to mitigate pulmonary fibrosis in the bleomycin lung injury mouse model – the preferred model for
evaluating candidate IPF therapeutics. Specific Aim 1 is a BIO 300 dose ranging study to determine the
therapeutic efficacy of BIO 300 to reduce pulmonary fibrosis and expression of disease-related biomarkers in
the bleomycin lung injury mouse model. Specific Aim 2 will assess the impact of combining BIO 300 with each
of the currently approved IPF drugs to determine if combination therapy provides an additional treatment benefit.
Specific Aim 3 will be to request and conduct a Type C meeting with the FDA to discuss the nonclinical data
obtained from the studies completed under the first two Specific Aims, and solicit guidance on future development
activities aimed at advancing BIO 300 toward clinical evaluation as an IPF treatment.
项目摘要
特发性肺纤维化(IPF)是一种严重的肺部疾病,其特征在于组织的进行性瘢痕形成
在肺里。IPF与预后特别差相关,大多数患者死于该病
从确诊之日起3-5年内。尼达尼布和吡非尼酮这两种抗纤维化治疗已被
近年来,基于其减缓肺功能下降速度的能力,批准用于治疗IPF
然而,在患者中,两种治疗都没有显示出导致患者质量的有意义的改善。
两者都有患者耐受性的问题。
Humanetics正在开发BIO 300,一种合成染料木黄酮的纳米混悬液,作为减轻肺部疾病的治疗方法。
由于肺部暴露在电离辐射下而导致的纤维化。染料木黄酮已被证明具有抗纤维化
通过抑制促炎和促纤维化,
典型NF-κB和TGF-β信号通路激活诱导的基因表达。基于这些
研究结果,我们假设BIO 300可能具有显著的治疗潜力,作为IPF患者的治疗方法。
重要的是,BIO 300已在两种健康受试者的临床研究中证明了卓越的临床安全性。
志愿者和肺癌患者接受放射治疗,这将简化其未来的临床路径
评估作为IPF治疗。
该SBIR项目的第1阶段目标是通过测量其在治疗IPF中的作用,评估BIO 300作为IPF治疗的效用。
减轻博来霉素肺损伤小鼠模型中肺纤维化的能力-博来霉素肺损伤小鼠模型是
评估候选IPF治疗剂。具体目标1是一项BIO 300剂量范围研究,以确定
BIO 300减少肺纤维化的治疗效果和疾病相关生物标志物的表达
博莱霉素肺损伤小鼠模型。具体目标2将评估将BIO 300与每种
目前获批的IPF药物,以确定联合治疗是否提供额外的治疗获益。
具体目标3是要求与FDA举行C类会议,讨论非临床数据
(c)就首两个特定目的已完成的研究取得的数据,并就未来的发展寻求指引
旨在推进BIO 300作为IPF治疗的临床评价的活动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL D KAYTOR其他文献
MICHAEL D KAYTOR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL D KAYTOR', 18)}}的其他基金
AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS
BIO 300 缓解肺炎和肺纤维化的 NHP 功效研究
- 批准号:
9915635 - 财政年份:2019
- 资助金额:
$ 29.85万 - 项目类别:
Prevention of erectile dysfunction following prostate cancer radiotherapy
预防前列腺癌放射治疗后的勃起功能障碍
- 批准号:
8714389 - 财政年份:2014
- 资助金额:
$ 29.85万 - 项目类别:
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 29.85万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 29.85万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 29.85万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 29.85万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 29.85万 - 项目类别:
Standard Grant